QPPV.COM KNOWLEDGE ASSESSMENT

Eculizumab Biosimilar: C5 Complement Blockade, Biosimilarity and Pharmacovigilance

Test your understanding of the concepts covered by Eculizumab Biosimilar: C5 Complement Blockade, Biosimilarity and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the central regulatory objective of a biosimilar development programme?

To repeat the entire independent clinical development programme of the reference medicine To demonstrate high similarity and exclude clinically meaningful differences using comparative analytical, functional, pharmacokinetic, immunogenicity and clinical evidence To establish a new mechanism of action that differs from the reference product To prove that the biosimilar is molecularly identical in every attribute to the reference product

Question 2 of 10 Which set of data would provide the most complete assessment of a suspected meningococcal infection during eculizumab treatment?

Only the date of the most recent infusion Vaccination dates, antimicrobial prophylaxis, organism and serogroup, microbiology, clinical syndrome, timing, treatment and outcome Only the patient's prior history of anaemia The biosimilar approval date without patient-level information

Question 3 of 10 Why should pharmacovigilance analyses use both active-substance-level and brand-level views?

Active-substance aggregation assesses class risks, while brand-level analysis supports traceability and detection of potential product-specific patterns Brand-level analysis is sufficient because mechanism never matters Active-substance aggregation should always replace product identification The two analytical levels provide identical information and therefore either one is unnecessary

Question 4 of 10 Which conclusion is most defensible when no product-specific safety difference is demonstrated after extensive comparison of an eculizumab biosimilar with its reference product?

Routine pharmacovigilance is no longer necessary because biosimilars are risk-free Class-level and product-level surveillance remain necessary because known mechanism-related risks, traceability needs and real-world exposure continue All future reports should be analysed only under the reference product name Meningococcal risk no longer applies to the biosimilar

Question 5 of 10 Which factor is particularly important when assessing a paediatric case involving an eculizumab product containing sorbitol?

Age, weight, dose schedule and assessment for hereditary fructose intolerance where relevant to the product used Only the patient's adult occupational history Whether the patient has previously used an unrelated oral antibiotic The number of reference-product indications listed in another jurisdiction

Question 6 of 10 Which set of information best reflects the four linked layers of high-quality eculizumab biosimilar pharmacovigilance?

Product traceability, complement-blockade controls, disease activity and treatment continuity Marketing expenditure, prescriber preference, hospital size and patient satisfaction Only adverse-event seriousness, expectedness, listedness and causality Molecular structure, company ownership, country of manufacture and price

Question 7 of 10 Which report is most complete for evaluating a suspected infusion reaction to an eculizumab biosimilar?

The event term alone, without exposure details Onset relative to infusion, infusion rate, dose number, clinical phenotype, intervention, interruption, rechallenge, product and batch Only the patient's vaccination history Only the indication for which eculizumab was prescribed

Question 8 of 10 Why should disseminated gonococcal infection also be considered in the safety surveillance of eculizumab?

It is an example of another Neisseria infection that may be facilitated by impaired terminal-complement defence It is the only infection prevented by meningococcal vaccination It demonstrates that eculizumab directly causes sexually transmitted infections It is unrelated to complement and therefore should be excluded from surveillance

Question 9 of 10 A patient with PNH has persistent anaemia despite biochemical control of intravascular haemolysis on eculizumab. What is the most appropriate pharmacovigilance interpretation?

The finding automatically proves that the biosimilar has lost C5-binding activity Persistent anaemia may reflect extravascular haemolysis, marrow failure, iron deficiency, infection or another cause and requires clinical clarification The finding proves that the patient has developed neutralising antidrug antibodies Anaemia is unrelated to PNH once LDH has improved

Question 10 of 10 Which statement best describes the pharmacological consequence of eculizumab binding to complement protein C5?

It prevents cleavage of C5 into C5a and C5b, thereby blocking terminal-complement effectors while leaving upstream complement activity partly intact It permanently depletes all circulating complement proteins, including C3 It directly inhibits antibody production by B cells It prevents formation of the alternative-pathway C3 convertase but does not affect terminal complement

Eculizumab Biosimilar: C5 Complement Blockade, Biosimilarity and Pharmacovigilance

Cookie Settings